🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCompounding & FormulationMy vial looks cloudy - throw it out?? — 6 month update

My vial looks cloudy - throw it out?? — 6 month update

A1cHero_PHX Wed, Mar 26, 2025 at 2:35 PM 14 replies 1,750 viewsPage 1 of 3
This thread is more than 14 months old. Information may be outdated. Consider searching for more recent discussions.
A1cHero_PHX
Member
523
2,678
Jul 2024
Phoenix, AZ
Mar 26, 2025 at 2:35 PM#1

Two pharmacies quoted me last year, one describing itself as 503A and one as 503B, and I assumed 503B just meant bigger until both stopped within weeks of each other.

Two things anyone can check: a state licence number for a 503A, and an FDA outsourcing-facility registration for a 503B. Both are publicly searchable, and a pharmacy unwilling to give you either has answered the question.

What I am after is why a shortage listing created a legal pathway at all, since a shortage is a supply fact rather than a permission.

Practical detail welcome, however dull — the duller the better.

48 1zoe_NC, Dr.ObesityLA, NurseKim_ATL and 45 others
Reply Quote Save Share Report
Dr.SportsMedIN
Senior Member
1,456
6,789
Feb 2024
Indianapolis, IN
Mar 26, 2025 at 3:19 PM#2

Short answer first, then the reasoning. The shortage clause is the answer to the second question and it is a subtraction rather than an addition. Both exemptions forbid compounding something that is essentially a copy of a commercially available approved product. A product FDA has listed as in shortage is not treated as commercially available, so listing removed the objection that otherwise blocked compounding. It never created a permission; it withdrew a prohibition, which is why it evaporated the moment the supply fact changed.

49 2lisa_labSD, adam_van, Dr.SurgeonPGH and 46 others
Reply Quote Save Share Report
andrew_nyc
Member
534
2,345
Apr 2024
New York, NY
Mar 26, 2025 at 4:03 PM#3
Dr.SportsMedIN said:
The shortage clause is the answer to the second question and it is a subtraction rather than an addition.

Agreed, and the enforcement dates were staggered by category — 503A first, 503B a few weeks later — because outsourcing facilities have manufactured inventory and clinic contracts to unwind while a 503A makes to order.

Last edited: Mar 26, 2025 at 9:03 PM
50 3PharmD_Rodriguez, julia.endo, JessicaM_2024 and 47 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
quinn_sf
Member
489
2,123
Jun 2024
San Francisco, CA
Mar 26, 2025 at 4:46 PM#4
A1cHero_PHX said:
Two pharmacies quoted me last year, one describing itself as 503A and one as 503B, and I assumed 503B just meant bigger until both stopped within…

Same position here, arrived at the long way round. They are two different exemptions from the same federal requirements and they buy different things. A 503A pharmacy is regulated primarily by the state board, needs a patient-specific prescription, is exempt from CGMP, and may use a bulk substance that has a USP monograph, is a component of an approved drug, or appears on the 503A bulks list — three independent doorways. A 503B outsourcing facility registers with the FDA, is inspected on a risk basis, must comply with CGMP, may compound for office stock without a patient-specific prescription, and has one doorway to a permitted bulk substance: the 503B bulks list, or the drug shortage list.

Last edited: Mar 26, 2025 at 10:46 PM
1 4andrew_nyc
Reply Quote Save Share Report
james_edin
Member
289
1,234
Sep 2024
Edinburgh, UK
Mar 26, 2025 at 8:50 PM#5

Clinical perspective, offered as context rather than as advice.

503A vs 503B compounding pharmacies for compounded supply — this distinction matters enormously:

Feature503A503B
RegulationState Board of PharmacyFDA-registered
PrescriptionRequired (patient-specific)Can compound without patient Rx
TestingVaries by statecGMP required
ScaleSmall batchesLarger production
Quality consistencyVariableGenerally higher

I strongly recommend 503B facilities. The FDA oversight and cGMP requirements mean more consistent product quality.

2 5bbq_ray_KC, oliver_london
Reply Quote Save Share Report

Similar Threads

503A vs 503B compounding — regulatory framework explained4 replies
Compounded semaglutide stability: accelerated degradation study results6 replies
Lyophilized vs liquid peptides — stability and bioavailability comparison18 replies
Bacteriostatic water sourcing and sterility considerations8 replies
State-by-state compounding pharmacy regulations — 2026 map8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register